All In Biotech

Drug Trial Radar · NCT04952597

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Limited-Stage Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Jul 15, 2021

Primary completion

Jul 26, 2023

Study completion Jul 26, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jul 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and cCRT when used in combination is expected to advance treatment options in the serious unmet medical need population of Limited-Stage Small Cell Lung Cancer (LS-SCLC) participants .

Conditions

  • Limited Stage Small Cell Lung Cancer

Interventions

  • OciperlimabDrug

    Ociperlimab 900 milligrams (mg) administered intravenously once every 3 weeks on Day 1 of each cycle

  • TislelizumabDrug

    Tislelizumab 200 mg administered intravenously once every 3 weeks on Day 1 of each cycle

  • Concurrent ChemoradiotherapyDrug

    Cisplatin/Carboplatin: Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles or carboplatin at a dose of area under the curve (AUC) 5 administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles. Etoposide: (100 mg/m2) administered intravenously on Days 1, 2, and 3 of each cycle for 4 cycles Thoracic radiation therapy (TRT): once daily fractions for 6 to 7 weeks for a total dose of 60 to 70 units of absorbed dose of ionizing radiation (Gy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to approximately 2 years

Locations

33 sites in 3 countries. Site status is shown where the registry gives one.

  • Tennessee Cancer Specialist

    Knoxville, Tennessee

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • The First Affiliated Hospital, Sun Yat Sen University

    Guangzhou, Guangdong, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Huai An First Peoples Hospital

    Huaian, Jiangsu, China

  • Nanjing Chest Hospital

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Hanzhong Central Hospital

    Hanzhong, Shaanxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Qingdao Central Hospital

    Qingdao, Shandong, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Affiliated Zhongshan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital)

    Ningbo, Zhejiang, China

  • Chungbuk National University Hospital

    Cheongju-si, Chungcheongbukdo, South Korea

  • Cha Bundang Medical Center, Cha University

    Gyeonggido, Gyeonggi-do, South Korea

  • The Catholic University of Korea, St Vincents Hospital

    Suwon, Gyeonggi-do, South Korea

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, Gyeongsangbukdo, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.